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Abstract
AIM: To evaluate long-term clinical course of Budd-
Chiari syndrome (BCS) and predictive factors associated 
with the development of hepatocellular carcinoma (HCC) 
and survival. 
METHODS: We analyzed 67 patients with BCS be-
tween June 1988 and May 2008. The diagnosis of BCS 
was confirmed by hepatic venous outflow obstruction 
shown on abdominal ultrasound sonography, computed 
tomography, magnetic resonance imaging, or venogra-
phy. The median follow-up period was 103 ± 156 [in-
terquartile range (IQR)] mo. 
RESULTS: The median age of the patients was 47 ± 
16 (IQR) years. At diagnosis, 54 patients had cirrhosis, 
25 (37.3%) Child-Pugh class A, 23 (34.3%) Child-Pugh 
class B, and six (9.0%) patients Child-Pugh class C. 
During the follow-up period, HCC was developed in 17 
patients, and the annual incidence of HCC in patients 
with BCS was 2.8%. Patients in HCC group (n  = 17) 
had higher hepatic venous pressure gradient (HVPG) 
than those in non-HCC group (n  = 50) (21 ± 12 mmHg 
vs  14 ± 7 mmHg, P  = 0.019). The survival rate of BCS 
patients was 86.2% for 5 years, 73.8% for 10 years, 
and 61.2% for 15 years. In patients with BCS and HCC, 
survival was 79% for 5 years, 43.1% for 10 years, and 
21.5% for 15 years. 
CONCLUSION: The incidence of HCC in patients with 
BCS was similar to that in patients with other etiologic 
cirrhosis in South Korea. The HVPG is expected to pro-
vide additional information for predicting HCC develop-
ment in BCS patients.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Budd-Chiari syndrome (BCS) is a rare hepatic disease 
caused by occlusion of  the hepatic venous outflow. 
Thrombogenic conditions among the known causes of  
BCS are well documented, such as coagulopathy, chronic 
intake of  contraceptives, myeloproliferative diseases, au-
toimmune diseases, and others[1]. Hepatic venous outflow 
block can also be caused by malignant tumors[2]. BCS 
was initially defined as a symptomatic occlusion of  the 
hepatic veins, but with increasing reports on various ob-
structive cases in the hepatic portion of  the inferior vena 
cava (IVC), it became to include obstructive IVC lesions 
as well as the major hepatic veins. BCS induces chronic 
liver congestion so that it causes hepatomegaly, ascites, 
leg edema, collateral venous dilatation in the body trunk 
and portal hypertension[3]. Several studies have suggested 
that hepatic congestion caused by obstruction of  hepatic 
venous outflow can lead to cirrhosis and hepatocellular 
carcinoma (HCC)[4,5]. The incidence of  HCC in patients 
with BCS has varied according to regions and investiga-
tors[3,6-9]. Japan and South Africa showed relatively higher 
incidences compared to those of  United States and 
France: 6.4%-47.5% vs 4%-20%[5,7,9,10]. Prognosis of  HCC 
in BCS has varied as well[5,6,11]. 
We followed BCS patients treated at our hospital for 
more than 20 years, and our long term follow-up data can 
be helpful to understand the prognosis of  BCS patients 
and natural course of  the disease. Thus, we (1) evaluated 
the incidence and cumulative annual risk of  HCC in BCS 
patients; (2) analyzed the characteristics associated with 
the development of  HCC in BCS patients; and (3) inves-
tigated the prognosis of  BCS and HCC in BCS patients.
MATERIALS AND METHODS
Patients
From June 1988 to May 2008, 95 consecutive patients 
who were diagnosed with BCS at Severance Hospital 
were studied retrospectively. Among them, 28 patients 
were excluded based on the criteria as follows: patients 
with secondary BCS [occlusion of  the hepatic venous 
outflow by an outside structure (HCC, a klatskin tumor, 
and renal cell carcinoma)], hematologic diseases which 
could result venous obstructive disease, hepatic septic 
emboli of  colon cancer, or post-operative complication 
of  HCC. Finally 67 patients who were diagnosed with 
primary BCS were investigated. The study protocol con-
formed to the ethical guidelines of  the 1975 Helsinki 
Declaration and was approved by the institutional review 
board of  our institute.
Methods
We retrospectively reviewed patients’ age, gender, and 
presenting symptoms of  decompensate liver cirrhosis 
such as ascites, encephalopathy and variceal bleeding. 
We also investigated their history of  medication which 
can induce thrombosis such as oral contraceptive, herbal 
medication, and steroid. Patients were assessed for other 
risk factors of  cirrhosis and HCC such as alcohol, hepati-
tis B virus and hepatitis C virus (HCV) infections.
Laboratory tests included complete blood count, pro-
thrombin time, alanine aminotransferase (ALT), bilirubin, 
albumin, creatinine, viral markers such as hepatitis B virus 
surface antigen (HBsAg) and anti-HCV antibody. Based 
on laboratory and physical examination results, Model for 
End-Stage Liver Disease (MELD) score and Child Pugh 
score were calculated to evaluate liver function. Every 3-6 
mo, imaging studies such as computed tomography (CT), 
ultrasonography or magnetic resonance imaging (MRI) 
were performed, and alpha-fetoprotein (AFP) level was 
checked for HCC surveillance. 
Diagnosis of BCS and HCC
The diagnosis of  BCS was confirmed by hepatic venous 
outflow obstruction shown on ultrasound sonography 
(US), contrast-enhanced CT, MRI, or venography. Patients 
were confirmed to have HCC according to the American 
Association for the Study of  Liver Disease practice guide-
lines for the HCC diagnosis[12]. Briefly, patients were di-
agnosed with HCC if  they had a tumor with a maximum 
diameter of  > 2 cm and the typical features of  HCC on 
dynamic CT (defined as enhancement in the arterial phase 
and early washout in the portal phase), and an AFP > 200 
ng/mL[12]. If  the maximum diameter of  the tumor was 1 
cm to 2 cm, dynamic CT and MRI were performed. HCC 
was diagnosed if  coincidental typical features of  HCC 
were noted. If  the tumor did not satisfy above criteria, a 
biopsy was performed. During hospital stay, abdominal 
ultrasonography was carried out to evaluate the presence 
of  cirrhosis and hepatocellular carcinoma.
Measurement of hepatic venous pressure gradient
The hepatic venous pressure gradient (HVPG) was mea-
sured through catheterization during venography or an-
gioplasty. Forty-five patients underwent venography or 
angioplasty when diagnosed with BCS or during follow up 
period. Patients were diagnosed with clinical liver cirrhosis 
if  they satisfied one or more of  the following 3 condi-
tions: (1) a platelet count < 100  000/μL and ultrasono-
graphic findings suggestive of  cirrhosis including a blunt-
ed, nodular liver edge accompanied by splenomegaly (> 12 
cm)[13,14]; (2) the presence of  esophageal or gastric varices; 
and (3) overt complications of  liver cirrhosis, including 
ascites, variceal bleeding, and hepatic encephalopathy. 
Statistical analysis
Statistical analysis was performed using the Statistical 
Package for the Social Sciences (SPSS, version 17.0). De-
scriptive statistics were computed for all variables, includ-
ing median ± interquartile range (IQR) and percentiles 
for continuous variables and frequencies for categorical 
factors. Mann-Whitney U test and χ 2-test were used to 
compare HCC and non-HCC groups. Kaplan-Meier anal-
ysis was performed to estimate the cumulative incidence 
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of  HCC from the time of  BCS diagnosis and survival of  
all BCS patients and those who developed HCC. To eval-
uate the factors associated with the development of  HCC 
in patients with BCS, multivariate Cox regression analysis 
was used. A two-sided P value < 0.05 was considered to 
indicate a significant difference.
RESULTS
Baseline clinical characteristics of the patients
The baseline characteristics of  the 67 patients are shown 
in Table 1. The site of  obstruction was IVC in 56 patients 
(83.6%), hepatic vein in five patients (7.4%), and both 
IVC and hepatic vein sites in six patients who were clas-
sified as “combined”. There was no patient with history 
of  chronic use of  medication such as oral contraceptive, 
herbal medication, and steroid. Patients with heavy alco-
hol consumption defined as over 80 g/d were 20 (29.9%). 
HBsAg was positive in 3 patients (4.5%) and there was 
no patient with positive for anti-HCV antibody. Fifty-
four patients had underlying liver cirrhosis at the time of  
BCS diagnosis. Twenty-five of  them (37.3%) were classi-
fied as Child-Pugh class A, 23 (34.3%) as class B, and six 
(9.0%) as class C. The median MELD score was 11 ± 6 
(IQR). Twenty three patients (34.3%) had decompensated 
liver cirrhosis symptoms such as variceal bleeding, un-
controlled ascites or hepatic encephalopathy higher than 
grade 3. Twenty-seven (40.3%) patients were treated with 
percutaneous angioplasty, four (5.9%) with shunt opera-
tion, three (4.5%) with transjugular intrahepatic portosys-
temic shunt (TIPS), and one (1.5%) with thrombolysis. 
Thirty-two (47.7%) patients received only symptomatic 
medical treatment. The median follow up period was 103 
± 156 (IQR) mo. 
Development of HCC in the patients with BCS
During follow-up periods, HCC was occurred in 17 pa-
tients. At the time of  diagnosis of  HCC, the median age 
of  the patients was 53 ± 12 (IQR) years, and time pe-
riod between diagnoses of  BCS and HCC was 51 ± 115 
(IQR) mo (Table 2). HCC was histologically confirmed 
in 2 patients with hepatic resection. According to the 
Kaplan-Meier analysis, as shown in Figure 1, the cumula-
tive probability was 18.5% at 5 years, 30.3% at 10 years, 
and 42.6% at 15 years. The annual occurrence of  HCC in 
BCS patients was 2.8%. 
We compared the baseline characteristics (at the time 
of  diagnosis with BCS) of  HCC group (n = 17) with non-
HCC group (n = 50). The differences between the two 
groups are shown in Table 3. There were no significant 
differences in the comparison of  age, gender, obstruction 
site, alcohol consumption and presence of  viral markers 
between two groups. HVPG was significantly higher in 
HCC group [21 ± 12 (IQR) mmHg] than in non-HCC 
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Table 1  Baseline clinical characteristics of patients with 
Budd-Chiari syndrome (n  = 67)
Characteristics Budd-Chiari syndrome 
Age (yr) 47 ± 16
Gender (male) 34 (50.7)
Obstruction site
   IVC 56 (83.6)
   Hepatic vein 5 (7.5)
   Combined 6 (9.0)
Alcohol consumption
  None/social/heavy (> 80 g/d) 32 (47.8)/15 (22.3)/20 (29.9)
Positive viral marker
 HBsAg/anti-HCV 3 (4.5)/0 (0)
Liver cirrhosis at diagnosis 54 (80.6)
Child-Pugh A/B/C 25/23/6 (37.3/34.3/9.0)
MELD score 11 ± 6 
Decompensate LC symptoms 23 (34.3)
Length of obstruction (cm) 2.0 ± 4.0
HVPG (mmHg) 15 ± 10
Laboratory data
   ALT (IU/L)   19 ± 17
   Bilirubin (mg/dL)   1.4 ± 1.3
   Albumin (g/dL)   3.8 ± 0.7
   Hemoglobin (g/dL) 12.3 ± 2.6
   Platelet count (k/μL) 109 ± 78
   Creatinine (mg/dL)   0.9 ± 0.2
   PT (%)   73 ± 27
Treatment modality
   Angioplasty 27 (40.3)
   Shunt operation 4 (5.9)
   TIPS 3 (4.5)
   Thrombolysis 1 (1.5)
   Symptomatic medical treatment 32 (47.7)
Median follow up period (mo) 103 ± 156
Data were expressed as median ± IQR or n (%). IVC: Inferior vena cava; 
HCV: Hepatitis C virus; HbsAg: Hepatitis B surface antigen; MELD: Model 
for End-Stage Liver Disease; LC: Liver cirrhosis; HVPG: Hepatic venous 
pressure gradient; ALT: Alanine aminotransferase; PT: Prothrombin time; 
TIPS: Transjugular intrahepatic portosystemic shunt; IQR: Interquartile 
range.
Table 2  Characteristics of the patients with hepatocellular 
carcinoma at the time point of diagnosis (n  = 17)
Variables HCC 
Age (yr) 53 ± 12
Time period from BCS to HCC (mo)   51 ± 115
Child-Pugh class
   A/B/C 6 (35.3)/8 (47.1)/3 (17.6)
Tumor stage (AJCC 6th)1
   Ⅰ/Ⅱ/Ⅲ/Ⅳ 8 (47.1)/6 (35.3)/3 (17.6)/0 (0)
Treatment modality
   TACE/TACI 9 (52.9)
   Intra-arterial chemotherapy 3 (17.6)
   Conservative management 3 (17.6)
   Operation 2 (11.9)
Prognosis
   Alive 12 (70.5)
   Death 3 (17.6)
   F/U loss 2 (11.9)
Data were expressed as median ± IQR or n (%). BCS: Budd-Chiari syn-
drome; HCC: Hepatocellular carcinoma; TACE: Transarterial chemo-
embolization; TACI: Transarterial chemo-infusion; F/U: Follow up; IQR: 
Interquartile range. 1AJCC 6th, American Joint Committee on Cancer stag-
ing system, 6th edition.
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Prognosis and survival of patients with BCS and 
patients who were diagnosed with HCC
We estimated the overall survival rates of  all 67 BCS 
patients using the Kaplan-Mayer method. The overall 
survival rate was 86.2% at 5 years, 73.8% at 10 years, and 
61.2% at 15 years (Figure 2). During the follow-up peri-
ods, three patients among 17 who were diagnosed with 
HCC died, and two of  them died from hepatic failure 
and the other from massive variceal bleeding. In HCC 
group, the 5-year survival rate was 79%, 10-year rate 
43.1%, and 15-year rate 21.5% (Figure 3). Meanwhile, 
non-HCC group (n = 50) showed significantly higher sur-
vival rates than HCC group: 93.4% for 5 years and 74.7% 
for 15 years (P < 0.001).
DISCUSSION
BCS is caused by obstruction of  hepatic venous outflow 
at any level from the small hepatic veins to the junction 
of  the IVC with the right atrium. There are two forms of  
BCS according to the obstruction site: primary hepatic 
vein obstruction (classical BCS) and obstruction of  the 
group [14 ± 7 (IQR) mmHg] (P = 0.019). However, in 
the multivariate Cox regression analysis, HVPG showed 
no significant difference between in HCC group and in 
non-HCC group (P = 0.452).
Annual probability: 2.8%/yr
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Figure 1  Cumulative probability of hepatocellular carcinoma in patients 
with Budd-Chiari syndrome (n = 17). 
Table 3  Comparison of baseline clinical characteristics be-
tween hepatocellular carcinoma group and non hepatocellular 
carcinoma group
Variables HCC 
(n  = 17)
Non HCC 
(n  = 50)
P  value
Age (yr) 47 ± 11 47 ± 18    0.863
Gender (male) 10 (58.8) 24 (48)    0.441
Obstructive site    0.264
   IVC 15 (88.2) 41 (82)
   Hepatic vein   2 (11.8) 3 (6)
   Combined       0 (0)   6 (12)
Alcohol consumption    0.329
   None   6 (35.3)   26 (52.0)
   Social   4 (23.5)   11 (22.0)
   Heavy (> 80 g/d)   7 (41.2)   13 (26.0)
Positive for HBsAg       0 (0)   3 (6.0)    0.554
LC at diagnosis  14 ( 82.4)   40 (80.0)    0.832
Decompensate LC symptoms   8 (47.1)   15 (28.0)    0.148
Child Pugh A/B/C 5/7/2 20/16/4    0.647
MELD score 11 ± 6 11 ± 6    0.778
Follow up period (mo)   103 ± 146   103 ± 160    0.648
Length of obstruction (cm)   1.0 ± 2.5   2.0 ± 4.4    0.144
HVPG (mmHg)   21 ± 12 14 ± 7    0.019
Laboratory data
   ALT (IU/L)   21 ± 21   18 ± 14    0.160
   Bilirubin (mg/dL)   1.5 ± 1.9   1.3 ± 1.3    0.521
   Albumin (g/dL)     3.6 ± 0.85     3.8 ± 0.72    0.245
   Hemoglobin (g/dL) 12.5 ± 4.1 12.3 ± 2.3    0.897
   Platelet count (k/μL)      97 ± 59.5    113 ± 80.7    0.559
   Creatinine (mg/dL)     0.9 ± 0.14    0.85 ± 0..24    0.798
   PT (%)   71 ± 31   74 ± 22    0.756
Survival (%) < 0.001
   5 yr 79 93.4
   10 yr    43.1
   15 yr    21.5 74.7
Data were expressed as median ± IQR or n (%). HCC: Hepatocellular 
carcinoma; IVC: Inferior vena cava; LC: Liver cirrhosis; MELD: Model for 
End-Stage Liver Disease; HVPG: Hepatic venous pressure gradient; ALT: 
Alanine aminotransferase; PT: Prothrombin time; IQR: Interquartile range.
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Figure 2  Overall survival of patients with Budd-Chiari syndrome.
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Figure 3  Comparison of survival between hepatocellular carcinoma 
Group (n = 17) and non-hepatocellular carcinoma group (n = 50). HCC: 
Hepatocellular carcinoma.
Non HCC group
P  < 0.001
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hepatic portion of  the inferior vena cava (IVCO). The 
IVCO form is common in Asia and Africa but rarely 
reported in Western countries[9,15]. Most of  our patients 
(83.6%) had the IVCO form, which is similar to previous 
studies which reported the predominance of  IVCO form 
in Asia. The major difference between classical BCS and 
IVCO is that the former is rarely associated with HCC, 
while the latter is frequently complicated by HCC[3,8]. In 
our study, HCC was developed in 17 of  67 patients, and 
the annual incidence was 2.8%, similar to the incidence in 
patients with other etiologic cirrhosis in South Korea[16,17]. 
Until now, the accurate pathogenesis of  HCC in BCS 
has not been elucidated yet. Gwon et al[6] suggested that 
chronic liver injuries and congestion caused by obstruc-
tion of  hepatic venous outflow might contribute to a fi-
brotic process and development of  nodular type of  HCC. 
Prolonged congestion can lead to hepatocyte necrosis, 
and its replacement with fibrous tissue results in fibrosis, 
which is assumed to be the mechanism of  cirrhosis and 
HCC development[18-20]. This hypothesis is supported by 
frequent findings of  liver parenchymal cirrhotic change 
adjacent to HCC in BCS context[7].
The HVPG was significantly higher in HCC group 
than non-HCC group in our study. HVPG has been ac-
cepted as the gold standard for assessing the severity of  
portal hypertension[21]. With the pathogenesis proposed 
above, the higher pressure gradient means a greater degree 
of  portal hypertension and hepatic congestion; this might 
have contributed to a higher pressure gradient in HCC 
group in our study. Our study that showed significantly 
high HVPG in HCC group is worthy, which supports 
the hypothesis of  development of  HCC in patients with 
BCS. Until now, there were several published reports to 
analyze the risk factors for HCC in patients with BCS. 
Although Moucari et al[7] showed that BCS patients with 
HCC compared with those without HCC presented with 
IVC obstruction more frequently, there was no report that 
showed direct differences of  pressure gradient as our data 
presented. For comparison, other published data concern-
ing the prevalence and characteristics of  HCC in patients 
with BCS were reviewed in Table 4.
Varying survival results of  BCS have been reported, 
and the 5-year survival rate ranges from 69% to 87%[22,23]. 
In our data, the overall survival rate was 86.2% for 5 
years, 73.8% for 10 years, and 61.2% for 15 years. In pa-
tients with BCS and HCC, the survival rate was 79% for 
5 years, 43.1% for 10 years, and 21.5% for 15 years in our 
study. This is comparable with the results of  other pub-
lished reports[6,24]. Improvement in availability and tech-
niques of  diagnostic tools and development of  treatment 
modalities may allow earlier diagnosis of  BCS patients 
and better prognosis[18-20].
Although our study has an advantage of  long-term 
follow up data of  patients with BCS, there are still some 
limitations. First, this was retrospective and therefore has 
the limitations of  such an investigational design. Another 
limitation was that the values of  HPVG obtained during 
venography were not checked in all patients. Because of  
invasiveness of  venography, it could not be performed 
on all patients for HVPG measurement. These days, 
Table 4  Prevalence and characteristics of hepatocellular carcinoma in patients with Budd-Chiari syndrome from the literature
Ref. Matsui et al [3] Shin et al [24] Moucari et al [7] Gwon et al [6]
Year, country 2000, Japan 2004, South Korea 2008, France 2010, South Korea
Study design Retrospective Retrospective Retrospective Retrospective
Study period Apr 1968-Feb 1999 Mar 1989-Aug 2001 1987-2005 Mar 1990-Nov 2008
No. of patient with BCS 12 73 97 98
HCC (%) 3 (25) 15 (20.5) 11 (11.3) 23 (23)
Cumulative incidence of HCC - - 4 yr 3% 1 yr 7.3%
7 yr 6% 5 yr 13.5%
14 yr 12% 10 yr 31.8%
Tx. for HCC Resection (1) TACE (11) TACE (7) TACE (20)
TAE (1) Resection (2) LT (3) TACE + LT (3)
iA chemotherapy (1) Conservative tx. (2) Conservative tx. (1)
Survival rate of HCC in patients with BCS
   Median survival period (mo) - 58 (range, 3-59) - -
   Cumulative survival - 1 yr 93% - 1 yr 90%
2 yr 84% 2 yr 85%
3 yr 72% 3 yr 61%
4 yr 61%
5 yr 46%
Risk factors for HCC in patients with BCS
   Risk factors Chronic congestion in the liver, caused by an 
outflow block of hepatic veins
- Male gender, Female gender2
Coagulopathy1,
IVC obstruction
   Analysis method No statistical analysis (mere presumption) - Univariate analysis Multivariate analysis
HCC: Hepatocellular carcinoma; BCS: Budd-Chiari syndrome; Tx.: Treatment; TAE: Transarterial embolization; TACE: Transarterial chemoembolization; 
iA: Intra-arterial; LT: Liver transplantation. 1Coagulopathy harbored factor V Leiden; 2Female gender showed an odds ratio of 6.02 with P < 0.001 in Cox 
regression analysis; IVC: Inferior vena cava.
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Doppler US is used to non-invasively assess the HPVG 
with portal vein velocity. Considering the low incidence 
of  BCS, a multicenter study should be performed to 
overcome the limitations of  patient number and insuf-
ficient information. Despite these limitations, this study 
is worthy to analyze the incidence and prognosis of  HCC 
in BCS with long-term follow-up periods in South Korea.
In conclusion, the annual incidence of  HCC in pa-
tients with BCS was similar to the incidence in patients 
with other etiologic cirrhosis in South Korea. Further-
more, the HVPG can be a possible predictive factor of  
BCS-associated HCC development. Thus, BCS patients 
who are expected to have high pressure gradient should 
be actively managed as a high risk group for HCC de-
velopment. An intervention to decrease the pressure 
gradient in BCS patients may be helpful to reduce the in-
cidence of  HCC. A large-scale study will be necessary to 
further investigate whether the treatment of  congestion 
decreases the incidence of  HCC.
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factor of BCS-associated HCC development. Thus, BCS patients who are 
expected to have a high pressure gradient should be actively managed as a 
high risk group for HCC development. An intervention to decrease the pressure 
gradient in BCS patients may be helpful to reduce the incidence of HCC.
Peer review
This study provides basic and essential data for the clinical care of the patients 
with BCS. 
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